Janney Montgomery Keeps 'Sell' on ImClone Systems

Analyst Brian Rye says the biotech's stock looks overvalued in an increasingly crowded cancer-drug space

Janney Montgomery reiterated its sell rating on ImClone Systems (IMCL ).

To continue reading this article you must be a Bloomberg Professional Service Subscriber.